Partner Nate Lacktman was quoted in an mHealth Intelligence article, “CMS Code Gives Docs a Chance to Use Store-and-Forward Telehealth,” about the Centers for Medicare & Medicaid Services’ decision to begin reimbursing providers using store-and-forward (asynchronous) telehealth to analyze and diagnose images sent to them from established patients.
Lacktman said it’s worth noting that many industry advocates supported coverage of this code for new patients, particularly in dermatology and ophthalmology. “This service could also be valuable in urology, as it would provide a way to assess new patients with conditions such as hematuria (blood in the urine) in a timely manner,” he said.
He pointed out, however, that the new code has its limitations. One is that it can only be used on established patients. Another is that it covers telemedicine technologies that involve pre-recorded, patient-generated still or video images submitted by the patient, not data derived from a questionnaire or survey. “CMS rejected proposals to include, within the scope of this code, email/messaging or questionnaires/assessments that do not include an image or other visual item,” he said.
Lacktman said it’s worth noting that many industry advocates supported coverage of this code for new patients, particularly in dermatology and ophthalmology. “This service could also be valuable in urology, as it would provide a way to assess new patients with conditions such as hematuria (blood in the urine) in a timely manner,” he said.
He pointed out, however, that the new code has its limitations. One is that it can only be used on established patients. Another is that it covers telemedicine technologies that involve pre-recorded, patient-generated still or video images submitted by the patient, not data derived from a questionnaire or survey. “CMS rejected proposals to include, within the scope of this code, email/messaging or questionnaires/assessments that do not include an image or other visual item,” he said.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”